Cysteinyl leukotrienes (CysLTs, including LTC4, LTD4, and LTE4) are important inflammatory mediators implicated in pathogenesisi of asthma. Zafirlukast (Accolate) is the first-approved LTD4 and LTE4 receptor antagonist which is used clinically to treat mild to moderate asthma. A single oral 40 mg dose of Zafirlukast treatment before subjects were challenged with aerosolized allergen significantly attentuated the early and late phase bronchoconstriction to inhaled allergen and suppressed the allergen-induced increase in non-specific bronchial reactivity[3]. MIN6 cells treated with zafirlukast for 1 h showed increased insulin secretion in a concentration-dependent manner in both low and high glucose conditions[4]. The glucose-lowering effect of zafirlukast (0.1 mg/g) was also observed in mice at 90 and 120 min during an intraperitoneal glucose tolerance test, with 29.3 ± 7.9% reduction for 90 min and 46.7 ± 6.6% reduction for 120 min, respectively[4].
United States, California
... 展开 >>
UCSF Helen Diller Family Comprehensive Cancer Center
Recruiting
San Francisco, California, United States, 94143-1711
Contact: Pamela N. Munster, MD 877-827-3222 cancertrials@ucsf.edu 收起 <<
搜索
